| Literature DB >> 33006031 |
Hajime Morohashi1, Yoshiyuki Sakamoto2, Takuya Miura2, Takuji Kagiya2, Kenta Ogasawara2, Yoshiya Takahashi2, Kentaro Sato2, Yutaro Hara2, Hirokazu Ogasawara2, Kenichi Hakamada2.
Abstract
BACKGROUND: Therapeutic strategies to suppress local recurrence, including lateral lymph node metastasis, are important to improve the curability of rectal cancer. The aim of the present study was to clarify the advantages of robotic-assisted laparoscopic lateral lymph node dissection (RALLD), comparing its short-term outcomes with those of laparoscopic lateral lymph node dissection (LLLD). There are some retrospective reports comparing RALLD or LLLD and open lateral lymph node dissection (OLLD), but few reports comparing RALLD and LLND to each other.Entities:
Keywords: Lateral lymph node dissection; Rectal cancer; Robotic-assisted laparoscopic surgery
Mesh:
Year: 2020 PMID: 33006031 PMCID: PMC8346387 DOI: 10.1007/s00464-020-07979-6
Source DB: PubMed Journal: Surg Endosc ISSN: 0930-2794 Impact factor: 4.584
Fig. 1Flowchart of patients. RALLD robotic-assisted laparoscopic lateral lymph node dissection. LLLD laparoscopic lateral lymph node dissection
Fig. 2Intraoperative view after right side lateral lymph node dissection of the a the internal lymph node area and b the obturator lymph node area
Characteristics of patients undergoing robotic-assisted or laparoscopic lateral lymph node dissection for rectal cancer
| RALLD ( | LLLD ( | |||
|---|---|---|---|---|
| Age | (years) [median(rage)] | 63 (37–75) | 63 (34–81) | 0.433 |
| Sex | 0.473 | |||
| Male | 31 (77.5) | 41 (72.7) | ||
| Female | 6 (22.5) | 14 (27.3) | ||
| BMI | (kg/m2) [median(rage)] | 22.8 (16.9–32.1) | 22.3 (16.0–29.2) | 0.610 |
| Tumor location from anal verge | (cm) [median(rage)] | 5 (0–8) | 5 (0–8) | 0.465 |
| cTNM Stage | 0.112 | |||
| I | 0 | 0 | ||
| II | 24 (60.0) | 22 (40.0) | ||
| III | 15 (37.5) | 28 (50.9) | ||
| IV | 1 (2.5) | 5 (9.1) | ||
| Preoperative chemoradiotherapy | 1 (2.5) | 0 | 0.382 | |
| Neoadjuvant chemotherapy | 32 (94.1) | 43 (78.2) | 0.042 | |
| History of laparotomy | 1 (2.5) | 4 (7.3) | 0.401 |
Comparison of perioperative outcomes between the two groups Values given are numbers (percentages) unless indicated otherwise
| RALLD ( | LLLD ( | ||
|---|---|---|---|
| Type of operation | < 0.001 | ||
| LAR | 20 (50.0) | 18 (32.7) | |
| ISR | 6 (15.0) | 15 (27.3) | |
| Hartmann's operation | 5 (12.5) | 3 (5.5) | |
| APR | 9 (22.5) | 19 (34.5) | |
| Bilateral lateral lymph node dissection | 33 (97.1) | 55 (100) | 0.788 |
| Conversion | 0.618 | ||
| Laparoscopy | 1 (2.5) | – | |
| Laparotomy | 0 | 1 (1.8) | |
| Operative time (min) [median(range)] Total Operative time | 507 (270–763) | 345 (230–609) | < 0.001 |
| Lateral lymph node dissection time | 125 (95—174) | 110 (119- 156) | 0.661 |
| Blood loss (ml) [median(range)] | 60 (0–880) | 80 (0–750) | 0.665 |
| Transfusion | 1 (2.5) | 0 | 0.513 |
| Days to soft diet (days) [median(range)] | 3 (3–7) | 3 (3–16) | 0.401 |
| Postoperative hospital time (days) [median(range)] | 14 (10–31) | 16 (8–82) | 0.048 |
RALLD robotic-assisted lateral lymph node dissection, LLLD laparoscopic lateral lymph node dissection
Comparison of postoperative complications between the two groups
| RALLD ( | LLLD ( | ||
|---|---|---|---|
| Incisional surgical site infection | 2 (5.0) | 3 (5.5) | 0.632 |
| organ/space surgical site infection | 3 (7.5) | 4 (7.3) | 0.669 |
| Postoperative bleeding | 0 | 0 | – |
| Small bowel obstruction | 0 | 0 | – |
| Anastomotic leakage | 1 (3.8) | 7 (21.2) | 0.031 |
| Urinary disfunction | 4 (10.0) | 7 (12.7) | 0.667 |
| Urinary infection | 1 (2.5) | 5 (9.1) | 0.132 |
| Obturator nerve paralysis | 3 (8.8) | 6 (10.1) | 0.641 |
Values given are numbers (percentages) unless indicated otherwise
RALLD robotic-assisted lateral lymph node dissection, LLLD laparoscopic lateral lymph node dissection
Comparison of pathological results between the groups
| RALLD ( | LLLD ( | ||
|---|---|---|---|
| pT | 0.064 | ||
| T0 (pathological complete response) | 9 (22.5) | 4 (7.3) | |
| T1 | 3 (7.5) | 2 (3.6) | |
| T2 | 10 (25.0) | 13 (23.7) | |
| T3 | 17 (42.5) | 34 (61.8) | |
| T4 | 1 (2.9) | 2 (3.6) | |
| pN | 0.111 | ||
| N0 | 27 (67.5) | 32 (58.2) | |
| N1 | 7 (17.5) | 15 (27.3) | |
| N2 | 6 (15.0) | 8 (14.5) | |
| pM | 0.351 | ||
| M0 | 39 (97.5) | 50 (90.9) | |
| M1 | 1 (2.5) | 5 (9.1) | |
| pStage | 0.284 | ||
| 0 (pathological complete response) | 8 (20.0) | 4 (7.3) | |
| I | 9 (22.5) | 14 (25.5) | |
| II | 9 (22.5) | 13 (23.6) | |
| III | 12 (32.5) | 19 (34.5) | |
| IV | 1 (2.5) | 5 (9.1) | |
| Lateral lymph node metastasis | 4 (10.0) | 8 (14.5) | 0.251 |
| Histological type | 0.338 | ||
| Well or moderately differentiated | 39 (97.5) | 53 (96.4) | |
| Poorly differentiated/mucinous carcinoma/signet ring cell | 1 (2.5) | 2 (3.6) | |
| Tumor size (mm) [median (range)] | 40 (0–60) | 40 (0–80) | 0.707 |
| Total lymph node dissection [median (range)] | 25 (3–59) | 26 (3–62) | 0.455 |
| Lateral lymph node dissection [median (range)] | 15 (1–32) | 13 (2–45) | 0.509 |
| Positive distal margin | 0 | 0 | – |
| Distance of distal margin (mm) [median (range)] | 20 (5–55) | 20 (5–55) | 0.331 |
| Positive resection margin | 1 (2.5) | 1 (1.8) | 0.634 |
Values given are numbers (percentages) unless indicated otherwise
RALLD robotic-assisted lateral lymph node dissection, LLLD laparoscopic lateral lymph node dissection